BCM
IMUX icon

Bridgeway Capital Management’s Immunic IMUX Stock Holding History

Bridgeway Capital Management’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,000
Closed -$21.3K – 1273
2025
Q4 		$21.3K Sell
4,000
-7,500
-65% -$54.9K ﹤0.01% 1212
2025
Q3 		$101K Hold
11,500
– – ﹤0.01% 1111
2025
Q2 		$80.2K Hold
11,500
– – ﹤0.01% 1099
2025
Q1 		$125K Sell
11,500
-10,000
-47% -$108K ﹤0.01% 1001
2024
Q4 		$215K Buy
21,500
+2,220
+12% +$28K ﹤0.01% 987
2024
Q3 		$318K Buy
19,280
+9,000
+88% +$128K 0.01% 966
2024
Q2 		$114K Hold
10,280
– – ﹤0.01% 1151
2024
Q1 		$136K Sell
10,280
-1,000
-9% -$13K ﹤0.01% 1173
2023
Q4 		$169K Sell
11,280
-3,500
-24% -$42.9K ﹤0.01% 1169
2023
Q3 		$217K Buy
14,780
+5,000
+51% +$96.1K 0.01% 1084
2023
Q2 		$245K Sell
9,780
-5,300
-35% -$88.8K 0.01% 1088
2023
Q1 		$225K Buy
15,080
+5,000
+50% +$92.8K 0.01% 1084
2022
Q4 		$141K Buy
10,080
+1,000
+11% +$27.3K ﹤0.01% 1162
2022
Q3 		$287K Buy
9,080
+5,300
+140% +$222K 0.01% 1056
2022
Q2 		$131K Sell
3,780
-6,000
-61% -$384K ﹤0.01% 1176
2022
Q1 		$1.1M Hold
9,780
– – 0.02% 757
2021
Q4 		$936K Sell
9,780
-2,300
-19% -$207K 0.02% 802
2021
Q3 		$1.07M Buy
+12,080
New +$1.19M 0.02% 800
2018
Q3 		– Sell
-467
Closed -$1.28M – 1447
2018
Q2 		$1.28M Buy
467
+125
+37% +$289K 0.01% 778
2018
Q1 		$929K Buy
342
+120
+54% +$275K 0.01% 878
2017
Q4 		$528K Sell
222
-216
-49% -$478K 0.01% 1078
2017
Q3 		$884K Buy
438
+88
+25% +$115K 0.01% 885
2017
Q2 		$406K Buy
350
+125
+56% +$167K ﹤0.01% 1144
2017
Q1 		$360K Hold
225
– – ﹤0.01% 1159
2016
Q4 		$392K Hold
225
– – 0.01% 1165
2016
Q3 		$551K Buy
+225
New +$555K 0.01% 1050

Other funds holding IMUX

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Bridgeway Capital Management's IMUX Position: Q1 2026 in Review

Bridgeway Capital Management sold out of Immunic (IMUX) in Q1 2026, closing a stake of 4,000 shares — an estimated $21.3K sold.

Bridgeway Capital Management first reported a position in IMUX in Q3 2016 and held it in 26 quarters. The position peaked at $1.28M in Q2 2018. 75 funds tracked by Wall St. Rank hold IMUX as of Q1 2026.

  • Bridgeway Capital Management reported no remaining Immunic position as of Q1 2026 after selling out during the quarter.
  • Bridgeway Capital Management sold 4,000 Immunic shares in Q1 2026, an estimated $21.3K.
  • Bridgeway Capital Management first reported a position in Immunic in Q3 2016 and held it in 26 quarters.
  • Bridgeway Capital Management's Immunic position peaked at $1.28M in Q2 2018.
  • 75 funds tracked by Wall St. Rank held Immunic as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.